Business Wire

CA-FORTANIX-INC

10.10.2023 09:01:32 CEST | Business Wire | Press release

Share
Fortanix Introduces New Data Sovereignty Solutions To Help Organizations Meet Evolving Global Data Security and Privacy Requirements

Fortanix® Inc., the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally. Available now, the existing and new features deliver several key capabilities, including support for sovereign cloud, storing keys in sovereign boundaries, anonymization of private data, centralized control to manage access and enforce consistent policies across hybrid and multicloud environments, and more, all delivered via an intuitive user experience.

Organizations around the globe are taking urgent steps to meet strict, complex, and changing data sovereignty regulations. According to a Gartner® report, “Particularly in Europe, but also in other regions, governments are becoming increasingly concerned due to tightening privacy and data protection regulations impacting data sovereignty, data control, technological sovereignty and their dependence on foreign cloud infrastructure providers.”*

Complying with multitude of mandates is a major challenge for organizations, but Fortanix makes it easy for them to ensure compliance over sensitive data, while also bolstering security. The Fortanix flagship DSM offering can be provisioned within customers’ sovereign regions, enabling them to have a dedicated solution that meets regulations in their legislative jurisdictions.

“Data sovereignty goes beyond just where data resides; it is a multi-layered approach that encompasses data security, protection, and privacy. Fortanix’s existing and new capabilities exemplify our commitment to expanding and enhancing DSM to deliver the most advanced data security and privacy solution to organizations around the globe,” said Faiyaz Shahpurwala, chief product and strategy officer at Fortanix. “Security and data teams can now maintain greater international and cross-border security, compliance, and control over their data with a unified platform that is powered by confidential computing and validated by the highest industry certifications.”

“Data sovereignty, data privacy and compliance with regulations such as GDPR and Schrems II are an integral part of our work in behavioral research,” said Raj Jagesar, project lead for the Digital Phenotyping Research Program (Behapp) at the University of Groningen in the Netherlands. “With Fortanix DSM's External Key Manager for Google Cloud, we have full control over our encryption keys not just for compliance purposes, but also to mitigate any security risks related to sensitive personal data.”

Fortanix DSM’s key data sovereignty capabilities include:

  • Full control over key generation and lifecycle management for hybrid, multicloud environments with natively integrated KMS and FIPS 140-2 Level 3 HSM
  • The ability to store encryption keys separate from data and within sovereign regions
  • Enforced least privileged data access with RBAC and Quorum Controls to support Zero Trust architecture
  • Crypto agility with rapid migration to latest approved quantum-proof cryptographic algorithms
  • Format-preserving encryption to anonymize sensitive data at ingestion or creation before sharing across pipelines and workflows to keep it private, usable, and compliant
  • Native database encryption to manage and store the keys required to encrypt all databases, including Oracle, SQL Server, MongoDB, PostGres, MySQL, Maria DB, IBM DB2, and more
  • Joint VMware and Fortanix solution for scalable data protection and compliance for VMware Sovereign cloud environments
  • Sovereign support for Google Cloud services/offerings in the Kingdom of Saudi Arabia, in partnership with SITE and CNTXT
  • Confidential data search, enabling users to quickly search for regulated data in encrypted databases at terabyte scale
  • Customer choice of deployment models: on-premises, virtual appliances running in private or public cloud, or a fully managed SaaS across multiple global regions

Fortanix Expands Client-Side Encryption to Gmail

Fortanix has added support for client-side encryption of Gmail messages, rounding out its offering as an external key manager for organizations working in the Google Workspace ecosystem. This means that data will never be sent from a knowledge worker end point such as an employee laptop without it being encrypted while in transit, boosting data privacy and security across the organization.

Fortanix now offers key management for all Google Workspace applications that use client-side encryption, including Docs, Sheets, Calendar, and now Gmail. This enables Fortanix customers who use Google Workspace to create, store, and manage encryption keys themselves, and not through Google.

Meet with Fortanix at it-sa Expo&Congress 2023

Fortanix will once again have a presence at it-sa Expo&Congress 2023, Europe's largest trade event for IT security. The event takes place Oct. 10-12 at Exhibition Centre Nuremberg in Nuremberg, Germany. Fortanix team members will be on hand in Hall 7, booth number 7-627.

For more information and to purchase tickets, visit the it-sa Expo&Congress website.

Additional Resources

About Fortanix

Fortanix secures data, wherever it is. Fortanix’s data-first approach helps businesses of all sizes to modernize their security solutions on-premises, in the cloud, and everywhere in between. Enterprises worldwide, especially in privacy-sensitive industries like healthcare, fintech, financial services, government, and retail, trust Fortanix for data security, privacy and compliance. Fortanix investors include Goldman Sachs, Foundation Capital, Intel Capital, In-Q-Tel, Neotribe Ventures and GiantLeap Capital. Fortanix is headquartered in Santa Clara, CA. For more information, visit https://www.fortanix.com.

*Gartner, What Are the Different Provider Approaches to ‘Sovereign Cloud’ Demands?, Rene Buest, Gregor Petri, Neville Cannon, Bart Willemsen, 4 April 2022

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231010355406/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye